Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Burkitt Lymphoma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Biphenotypic, Acute 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 51fludarabine 37Dexamethasone 35venetoclax 30pembrolizumab 25Rituximab 21pomalidomide 18Lenalidomide 18Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 12carfilzomib 11Temozolomide 11Injections 10Cisplatin 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Bortezomib 9Azacitidine 9selinexor 8Vincristine 8Immunotherapy, Adoptive 8Carboplatin 8obinutuzumab 7cemiplimab 7Drug Therapy 7Bevacizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Inotuzumab Ozogamicin × 1 year × Clear all
NCT06287229 2026-04-24

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence

NCT06863259 2026-02-18

Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

Children's Hospital Medical Center, Cincinnati

Phase 1 Recruiting
28 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡